Abstract
Purpose:
This trial was conducted to evaluate the effects of oligofructose-enriched
inulin on some of cardiovascular disease risk factors in women with type 2
diabetes.
Methods:
52 females (25<BMI<35 kg/m2) with
type 2 diabetes were randomly assigned to two groups. Participants received
10g/d oligofructose-enriched inulin (n=27) or 10g/d placebo (n=25) for 8 weeks.
Fasting blood samples were taken to measure metabolic profiles, malondialdehyd
and antioxidant enzymes at baseline and after the 8 weeks intervention. Paired,
unpaired sample t-test and analysis of covariance were used to comparison of
quantitative variables.
Results:
After 8 weeks, in the oligofructose-enriched inulin
group there was a significant increase in total antioxidant capacity (0.2
mmol/l, 20.0%) and a significant decrease in fasting plasma glucose (19.2
mg/dL, 9.4%) HbA1c (0.5%, 8.4%), total cholesterol (TC) (28.0 mg/dL, 14.1%),
low-density lipoprotein cholesterol (LDL-c) (22.0 mg/dL, 21.7%), TC/HDL-c ratio
(0.73, 20.7%), LDL-c/HDL-c ratio (0.55, 27.5%) and malondialdehyd (1.7 nmol/ml,
39.7%) compared to the placebo group. Changes in concentrations of
triglycerides, high-density lipoprotein cholesterol (HDLc), superoxide
dismutase, catalase and glutathione peroxidase were not significant in
oligofructose-enriched inulin group compared to the placebo group.
Conclusion:
Oligofructose-enriched inulin may improve glycemic
indices, lipid profile, antioxidant status and malondialdehyd in women with
type 2 diabetes.